Biotechnology / Industrial Enzymes and Microbial Solutions
Strategic Profile
Novonesis's biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
Cyborg Score Rationale
Novonesis holds market-leading positions in industrial enzymes and microbial solutions with high growth trajectory post-merger. The company benefits from strong synergies, global presence, and exposure to secular trends in sustainability and bioenergy. Recent integration execution and operating leverage will be key metrics to monitor.
Top Insights
Market leader with ~50% share in industrial enzymes and microbial solutions post-merger
Revenue grew from $2.65B (2023) to $3.98B (2024), demonstrating strong post-merger integration
Diversified customer base across 30+ industries and 130+ markets provides revenue stability
Positioned to benefit from growing demand for sustainable and bio-based solutions globally
Named Competitors
Specialty Enzymes — Enzyme and specialty ingredients provider
Industrial Biotechnology — Large diversified chemicals with biotech solutions
Biopharmaceutical Ingredients — Specialty chemicals and biotech ingredients
Recent Developments
(January 2024) Merger completion of Novozymes and Chr. Hansen to form Novonesis